Why did OMI's stock price hit a 52-week low?

**Bottom line 📝** Owens & Minor (OMI) slid to a 52-week low largely because its Q3 2025 results and forward narrative amplified worries about profitability and strategic execution, outweighing modest revenue growth. --- ### What pushed the shares down? | Key Pressure Point | Details | Why Investors Reacted | | --- | --- | --- | | Earnings miss on profitability | • GAAP net loss widened to **-$150 M** vs. -$13 M last year. • Adjusted EBITDA fell **14% YoY** to $92 M. | Signals weakening core earnings power just as the firm needs cash to fund its pivot. | | Strategic divestiture & “pivot risk” | Management is selling the Products & Healthcare Services segment to become a pure-play home-care company. | While simplification can unlock value long-term, investors fear near-term execution risk and “stranded” overhead costs (~$40 M/yr). | | Looming contract loss | OMI disclosed it may lose a **major customer in 2026**, trimming future revenue visibility. | Raises questions about scale advantages and bargaining power in its remaining business. | | Goodwill impairment & special charges | A **$106 M goodwill write-down** and **$772 M loss on assets held for sale** deepened the headline loss. | Large one-time charges spooked the market and highlighted balance-sheet fragility. | | Guidance not soothing enough | FY 2025 revenue guide of **$2.76–$2.82 B** is only ~2–4% growth and relies on flawless execution of the home-care pivot. | Lacks a compelling near-term catalyst to re-rate the stock. | ### How the market processed it 📉 • The stock fell **~5% in after-hours** trading post-earnings to $5.22 and subsequently drifted toward its 52-week low of **$4.34** as sellers digested the above headwinds. • With sentiment already fragile across smaller healthcare distributors, the combination of soft margins, restructuring uncertainty, and contract risk tipped the balance toward caution. --- ### So, what’s next? 1. **Execution watch:** Investors will demand evidence that management can close the divestiture smoothly, strip out stranded costs, and expand margins in Patient Direct. 2. **Customer diversification:** Replacing the at-risk 2026 contract is critical; expect management updates on pipeline wins. 3. **Cash-flow credibility:** Reducing debt and funding tech/automation initiatives without further dilution will be scrutinized. --- 🤔 **Your move:** Given OMI’s heightened volatility and restructuring risk, how comfortable are you with turnaround plays that might take 12–24 months to materialize—and how does that align with your short-term momentum focus?